Patents by Inventor Jose Enrique Montero Casimiro

Jose Enrique Montero Casimiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-CD6 ANTIBODY COMPOSITIONS AND METHODS FOR TREATING AND REDUCING NEGATIVE EFFECTS OF A CORONAVIRUS INCLUDING COVID-19
    Publication number: 20230151107
    Abstract: The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive immune response, such as the high expression levels of cytokines.
    Type: Application
    Filed: March 3, 2021
    Publication date: May 18, 2023
    Inventors: Pradip NAIR, Jose Enrique Montero CASIMIRO, Kiran MAZUMDARSHAW, Usha BUGHANI, Sandeep Nilkanth ATHALYE, Melarkode Subbaraman RAMAKRISHNAN, Tania CROMBET RAMOS, Kalet LEÓN MONZÓN, Mayra RAMOS SUZARTE
  • METHODS OF MAKING AND USING REGULATORY T CELLS AND EFFECTOR T CELLS HAVING CHIMERIC ANTIGEN RECEPTORS TARGETED TO CD6, CD19, AND/OR AN IL-13R FOR TREATMENT OF AUTOIMMUNE DISORDERS AND CANCERS
    Publication number: 20230076643
    Abstract: Provided herein are, inter alia, CAR-T cell compositions targeting CD6, CD19, and/or an IL-13R, and methods useful for treating autoimmune diseases and cancer.
    Type: Application
    Filed: December 30, 2020
    Publication date: March 9, 2023
    Inventors: Jose Enrique Montero Casimiro, Bart Otto Roep, Christine E. Brown
  • COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20220073637
    Abstract: Provided herein are, inter alia, anti-CD6 antibody-growth factor complexes including an anti-CD6 antibody portion bound to a growth factor protein (e.g., EGF) through a linker, which may be cleavable by a protease (e.g., diabetic microenvironment specific protease). The compositions provided herein are, inter alia, useful for the treatment of autoimmune diseases (e.g., type I diabetes).
    Type: Application
    Filed: July 1, 2019
    Publication date: March 10, 2022
    Inventors: Jose Enrique Montero CASIMIRO, Bart Otto ROEP, John Charles WILLIAMS
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20220025038
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: May 4, 2021
    Publication date: January 27, 2022
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • CD6 TARGETED CHIMERIC ANTIGEN RECEPTORS FOR TREATENT OF CERTAIN AUTOIMMUNE DISORDERS
    Publication number: 20210395329
    Abstract: Provided herein are, inter alia, CD6 targeting CAR-T cell compositions and methods useful for treating autoimmune diseases (e.g., Type I diabetes).
    Type: Application
    Filed: July 1, 2019
    Publication date: December 23, 2021
    Inventors: Jose Enrique Montero Casimiro, Bart Otto Roep, Christine E. Brown
  • METHODS OF ISLET CELL CULTURE
    Publication number: 20210355448
    Abstract: Provided herein are, inter alia, methods, compositions, and kits for culturing and improving the quality of islet cells. Included are compositions and kits for the ex vivo culture of islets or islet cells as well as methods of making and using the same. Isolated and cultured islets and islet cells are also provided.
    Type: Application
    Filed: June 26, 2018
    Publication date: November 18, 2021
    Inventors: Jose Enrique Montero CASIMIRO, Bart Otto ROEP, Ismail H. AL-ABDULLAH
  • Use of a CD6 binding partner and method based thereon
    Patent number: 11028168
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: June 8, 2021
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20210122829
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: April 29, 2020
    Publication date: April 29, 2021
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
  • Monoclonal antibody and a method thereof
    Patent number: 10669346
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 2, 2020
    Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • USE OF A CD6 BINDING PARTNER AND METHOD BASED THEREON
    Publication number: 20190345247
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Application
    Filed: December 10, 2018
    Publication date: November 14, 2019
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, BALA S. MANIAN, ABHIJIT BARVE, USHA BUGHANI, JOSE ENRIQUE MONTERO CASIMIRO
  • Methods for controlling fucosylation levels in proteins
    Patent number: 10308970
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: June 4, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Rasika Venkataraman, Laxmi Adhikary, Ankur Bhatnagar, Sunaina Prabhu, Kriti Shukla, Dinesh Baskar, Saravanan Desan, Harish Venkatraman Pai, Jose Enrique Montero Casimiro
  • Use of a CD6 binding partner and method based thereon
    Patent number: 10189899
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 29, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • A MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20180258179
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 13, 2018
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ
  • Monoclonal antibody and a method thereof
    Patent number: 10000573
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 19, 2018
    Assignees: CENTRO DE IMMUNOLOGIA MOLECULAR, BIOCON LIMITED
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • METHODS FOR CONTROLLING FUCOSYLATION LEVELS IN PROTEINS
    Publication number: 20180087080
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 29, 2018
    Inventors: PRADIP NAIR, RAMAKRISHNAN MELARKODE, RASIKA VENKATARAMAN, LAXMI ADHIKARY, ANKUR BHATNAGAR, SUNAINA PRABHU, KRITI SHUKLA, DINESH BASKAR, SARAVANAN DESAN, HARISH VENKATRAMAN PAI, JOSE ENRIQUE MONTERO CASIMIRO
  • Methods for controlling fucosylation levels in proteins
    Patent number: 9856502
    Abstract: The present invention relates to a method or process for controlling, inhibiting or reducing protein fucosylation in a eukaryote and/or a eukaryotic protein expression system. Said method comprises carrying out the protein expression and/or post-translational modification in the presence of an elevated total concentration of manganese or manganese ions.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 2, 2018
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Rasika Venkataraman, Laxmi Adhikary, Ankur Bhatnagar, Sunaina Prabhu, Kriti Shukla, Dinesh Baskar, Saravanan Desan, Harish Venkatraman Pai, Jose Enrique Montero Casimiro
  • Pharmaceutical compositions for the treatment of tumors expressing EGFR and GM3 N-glycolyl ganglioside (NeuGcGM3)
    Patent number: 9790279
    Abstract: The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: October 17, 2017
    Assignee: CENTRO DE IMMUNOLOGIA MOLECULAR
    Inventors: Adys González Palomo, Adriana Carr Perez, Kalet León Monzón, Rancés Blanco Santana, María del Carmen Barroso Alvarez, Amparo Emilia Macías Abraham, José Enrique Montero Casimiro
  • Monoclonal antibody and a method thereof
    Patent number: 9670285
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 6, 2017
    Assignees: BIOCON LIMITED, CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
  • PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-CD6 MONOCLONAL ANTIBODY USED IN THE DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS
    Publication number: 20170066835
    Abstract: The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen CD6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of Autoimmune Diseases, particularly the Rheumatoid Arthritis.
    Type: Application
    Filed: November 16, 2016
    Publication date: March 9, 2017
    Inventors: JOSE ENRIQUE MONTERO CASIMIRO, ANGEL RAIMUNDO CASACO PARADA, ZAIMA MAZZORA HERRERA, RUBY ALONSO RAMIREZ, ROLANDO PEREZ RODRIGUEZ
  • MONOCLONAL ANTIBODY AND A METHOD THEREOF
    Publication number: 20160168256
    Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Inventors: RAMAKRISHNAN MELARKODE, PRADIP NAIR, SUNDARAJ DAVID RAJKUMAR, KEDARNATH NANJUND SASTRY, MONALISA CHATTERJI, LAXMI ADHIKARY, HEMA BALASUBRAMANIAN, JOSE ENRIQUE MONTERO CASIMIRO, JOSEFA LOMBARDERO VALLADARES, ROLANDO PEREZ RODRIGUEZ